Our mission is to work on novel ways to prevent and treat HIV, COVID-19 and other emerging infections.
The mission of the Columbia Research Unit is to advance the science of HIV, SARS-CoV-2 and other emerging infections. We do that by working on the development of an effective vaccine and other biomedical interventions to prevent HIV, conducting studies that set the standards of care for people living with HIV, studying the impact of COVID-19, and pursuing vaccine and antibody based strategies to prevent and treat COVID-19. It is through community engagement and clinical studies within the Division of Infectious Diseases at the Columbia University Irving Medical Center that we hope to accomplish those goals.
Sponsored by the National Institutes of Health, we are a part of the international networks of the HIV Vaccine Trials Network (HVTN), the COVID Prevention Network (CoVPN), and the AIDS Clinical Trials Group (ACTG).
Our research collaborators include the Aaron Diamond AIDS Research Center (ADARC) at Columbia, HIV Center for Clinical and Behavioral Studies, and Project ACHIEVE of the New York Blood Center. Together, we form the NIH-funded Columbia Collaborative HIV/AIDS Clinical Trials Unit (Columbia Collaborative CTU).